GlassScriptPhysician profile
Jontel Pierce
NPI 1154686061
$5,244.16
in general payments reported to CMS, 2019-2025
38 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $67.16 · 2021: $473 · 2022: $1,636 · 2023: $528 · 2024: $1,056 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,149.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,328.64 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $585.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $340.40 | 2021-2025 | |
| Ucb, INC. | $338.06 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Allergan, INC. | $276.62 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $253.21 | 2019-2022 | |
| Eisai INC. | $224.66 | 2024-2025 | |
| Abbott Laboratories | $216.97 | 2019-2025 | Infinity |
| Genentech USA, INC. | $213.55 | 2019-2025 | Ocrevus Zunovo |
| Pfizer INC. | $206.94 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $189.78 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $155.75 | 2019-2024 | |
| Horizon Therapeutics Plc | $143.52 | 2023 | Uplizna |
| Lilly USA, LLC | $98.35 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Lundbeck LLC | $98.15 | 2021-2025 | Vyepti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $70.31 | 2022 | |
| Boston Scientific Corporation | $67.58 | 2023-2024 | Vercise |
| Biohaven Pharmaceuticals, INC. | $64.96 | 2021 | |
| Neurocrine Biosciences, INC. | $46.76 | 2024-2025 | Ingrezza |
| Ge Healthcare | $39.46 | 2019 | |
| Upsher-Smith Laboratories LLC | $38.03 | 2020-2021 | |
| Corium, LLC | $25.63 | 2024 | Azstarys |
| Amneal Pharmaceuticals LLC | $24.57 | 2025 | Crexont |
| Neurelis, INC. | $20.78 | 2022 | |
| Axsome Therapeutics, INC. | $19.00 | 2025 | Symbravo |
| Brainsway USA INC | $18.16 | 2022 | |
| Biogen, INC. | $16.41 | 2021 | |
| Grifols USA, LLC | $16.16 | 2021 | |
| Impel Pharmaceuticals INC. | $15.34 | 2023 | Trudhesa |
| Sk Life Science, INC. | $14.75 | 2021 | |
| Grt US Holding, INC. | $13.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.29 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.02 | 2019 | |
| Aquestive Therapeutics, INC. | $12.71 | 2020 | |
| Greenwich Biosciences, INC. | $12.10 | 2019 | |
| Aucta Pharmaceuticals, INC. | $11.95 | 2024 | Motpoly Xr |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jontel Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.